ArticleFrontiers in pharmacology2025
Influence of the type of volatile anesthetic on the development of acute kidney injury after endovascular repair of aortic aneurysm: a randomized controlled trial (DESEVAR study).
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03917186 (Fast-track in Endovascular Aortic Aneurysm Repair With Desflurane and Sevoflurane), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fast-track in Endovascular Aortic Aneurysm Repair With Desflurane and Sevoflurane: a Randomized Clinical Trial
Who cites it
1 citing paper in PubMed.
- New insights into contrast-associated acute kidney injury: the key role of endothelial dysfunction.Frontiers in nephrology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury (AKI) frequently occurs after endovascular aortic aneurysm repair (EVAR), leading to significant morbidity and mortality. It is associated with contrast administration, hypovolemia, arterial microembolization due to renal artery manipulation, ischemia-reperfusion syndrome, and other patient comorbidities. However, little is known about the effect of volatile anesthetics on the development of AKI in this context. Therefore, we aimed to investigate renal function in patients anesthetized with desflurane or sevoflurane for EVAR. For this, we conducted a single-center randomized clinical trial involving 80 patients scheduled for elective EVAR under general anesthesia. Patients were randomly assigned to the desflurane or sevoflurane anesthesia group. Biochemical variables of kidney function and biomarkers for AKI were studied at three different time points: before surgery, after surgery, and 24 h after surgery. Plasma creatinine, cystatin C, estimated glomerular filtration, uric acid, and kidney injury molecule-1 did not significantly change between both groups. A mixed linear model demonstrated a significant interaction (p = 0.01) of plasma neutrophil gelatinase-associated lipocalin (NGAL) between sevoflurane and desflurane. Both groups showed a progressive increase in plasma NGAL (sevoflurane 3.713 ng/mL, p < 0.001 and desflurane 1.774 ng/mL, p < 0.001) when comparing the moment before surgery with respect to 24 h after surgery. However, sevoflurane caused a higher plasma NGAL concentration than desflurane after 24 h of surgery (8.66 ± 5.09 ng/mL vs. 6.51 ± 3.86 ng/mL, P = 0.03). Desflurane was associated with a lower postoperative AKI than sevoflurane in patients undergoing EVAR. Further research is required to corroborate our results and evaluate the clinical importance. Trial registration: EudraCT: 2016-003906-16; ClinicalTrials.gov: NCT03917186.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.